UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple myeloma (66) 66
life sciences & biomedicine (63) 63
science & technology (63) 63
newly diagnosed (53) 53
humans (44) 44
hematology (42) 42
oncology (32) 32
multiple myeloma - drug therapy (26) 26
male (25) 25
aged (24) 24
female (24) 24
middle aged (22) 22
patients (22) 22
lenalidomide (21) 21
treatment outcome (20) 20
newly diagnosed multiple myeloma (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
multiple myeloma - mortality (18) 18
myeloma (17) 17
adult (16) 16
aged, 80 and over (15) 15
multiple myeloma - therapy (15) 15
thalidomide - analogs & derivatives (15) 15
clinical trials (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
bortezomib (13) 13
care and treatment (12) 12
dexamethasone (11) 11
thalidomide - administration & dosage (11) 11
multiple myeloma - diagnosis (10) 10
clinical trials as topic (9) 9
dexamethasone - administration & dosage (9) 9
medical diagnosis (9) 9
stem cells (9) 9
antineoplastic agents - therapeutic use (8) 8
cancer (8) 8
disease-free survival (8) 8
maintenance (8) 8
medical treatment (8) 8
thalidomide (8) 8
thalidomide - therapeutic use (8) 8
carfilzomib (7) 7
disease progression (7) 7
drug therapy (7) 7
hematology, oncology and palliative medicine (7) 7
retrospective studies (7) 7
survival analysis (7) 7
transplantation, autologous (7) 7
transplants & implants (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
chemotherapy (6) 6
clinical outcomes (6) 6
general & internal medicine (6) 6
hematopoietic stem cell transplantation (6) 6
medical research (6) 6
medicine, general & internal (6) 6
multiple myeloma - pathology (6) 6
neoplasm staging (6) 6
newly diagnosed myeloma (6) 6
quality of life (6) 6
stem cell transplantation (6) 6
survival rate (6) 6
transplantation (6) 6
analysis (5) 5
bortezomib - therapeutic use (5) 5
diagnosis (5) 5
drug administration schedule (5) 5
drug dosages (5) 5
elderly (5) 5
medicine & public health (5) 5
medicine, experimental (5) 5
melphalan (5) 5
oligopeptides - therapeutic use (5) 5
pain (5) 5
patient outcomes (5) 5
pharmacology & pharmacy (5) 5
prednisone (5) 5
proteasome inhibitor (5) 5
survival (5) 5
thalidomide - adverse effects (5) 5
therapy (5) 5
anemia (4) 4
autografts (4) 4
cancer research (4) 4
confidence intervals (4) 4
cost analysis (4) 4
decision making (4) 4
dexamethasone - adverse effects (4) 4
dexamethasone - therapeutic use (4) 4
health status (4) 4
immunologic factors - therapeutic use (4) 4
induction (4) 4
initiation (4) 4
lymphoma (4) 4
medical prognosis (4) 4
prognosis (4) 4
relapsed/refractory (4) 4
safety (4) 4
steroids (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2007, Volume 357, Issue 21, pp. 2133 - 2142
Journal Article
Blood, ISSN 0006-4971, 07/2005, Volume 106, Issue 1, pp. 35 - 39
...) as primary therapy in preparation for autologous peripheral blood stem-cell (PBSC) transplantation for multiple myeloma (MM... 
Life Sciences & Biomedicine | Hematology | Science & Technology
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 01/2019, Volume 106, pp. 89 - 98
Novel efficacious treatments with long-term tolerability are needed for transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients... 
Elderly | Oral therapy | Multiple myeloma | Newly diagnosed | Transplant-ineligible | Life Sciences & Biomedicine | Oncology | Science & Technology | Glycine - analogs & derivatives | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Glycine - adverse effects | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Cyclophosphamide - adverse effects | Multiple Myeloma - drug therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Aged, 80 and over | Female | Contraindications, Procedure | Glycine - administration & dosage | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Administration, Oral | Europe | Disease Progression | Progression-Free Survival | Boron Compounds - adverse effects | Aged | Australia | Eligibility Determination | Medical research | Cyclophosphamide | Dexamethasone | Stem cells | Medicine, Experimental | Transplantation | Steroids | Effectiveness | Toxicity | Medical treatment | Maintenance | Medical diagnosis | Patients | Older people | Toxic diseases | Neutropenia | Geriatrics | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Haematologica (Roma), ISSN 0390-6078, 07/2020, Volume 105, Issue 7, pp. 1937 - 1947
In the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Index Medicus
Journal Article
Therapeutic advances in hematology, ISSN 2040-6215, 12/2019, Volume 10, pp. 204062071989487 - 2040620719894871
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Clinical trials | Multiple myeloma
Journal Article